Xbrane Biopharma AB (publ)

OM:XBRANE Stock Report

Market Cap: SEK 395.3m

Xbrane Biopharma Future Growth

Future criteria checks 6/6

Xbrane Biopharma is forecast to grow earnings and revenue by 56.8% and 25% per annum respectively. EPS is expected to grow by 70.7% per annum. Return on equity is forecast to be 34.3% in 3 years.

Key information

56.8%

Earnings growth rate

70.66%

EPS growth rate

Biotechs earnings growth22.2%
Revenue growth rate25.0%
Future return on equity34.31%
Analyst coverage

Low

Last updated12 May 2025

Recent future growth updates

Recent updates

Analysts Are Betting On Xbrane Biopharma AB (publ) (STO:XBRANE) With A Big Upgrade This Week

Apr 04
Analysts Are Betting On Xbrane Biopharma AB (publ) (STO:XBRANE) With A Big Upgrade This Week

Investors Still Aren't Entirely Convinced By Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Despite 33% Price Jump

Mar 21
Investors Still Aren't Entirely Convinced By Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Despite 33% Price Jump

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Sep 30
Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05
Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21
Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Jun 04
Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Nov 05
We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Earnings and Revenue Growth Forecasts

OM:XBRANE - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027734312N/AN/A2
12/31/2026382111N/AN/A2
12/31/2025583300N/A3002
3/31/2025278-161-165-89N/A
12/31/2024199-265-186-134N/A
9/30/2024200-293-344-309N/A
6/30/2024192-329-431-419N/A
3/31/2024191-349-465-463N/A
12/31/2023239-322-423-407N/A
9/30/2023189-285-467-441N/A
6/30/2023144-246-427-390N/A
3/31/2023112-189-340-296N/A
12/31/202258-169-254-194N/A
9/30/202243-146-216-139N/A
6/30/202232-147-229-127N/A
3/31/202215-172-282-182N/A
12/31/202111-183-297-220N/A
9/30/20218-213-278-227N/A
6/30/20215-219-286-268N/A
3/31/20213-215-160-147N/A
12/31/2020N/A-218-242-238N/A
9/30/2020N/A-222-169-165N/A
6/30/2020N/A-210-146-145N/A
3/31/2020N/A-204-180-179N/A
12/31/2019N/A-188-150-149N/A
9/30/20195-154-118-117N/A
6/30/20197-5602N/A
3/31/201912-4002N/A
12/31/201820-13N/A47N/A
9/30/2018250N/A-4N/A
6/30/201823-69N/A-47N/A
3/31/201823-45N/A-36N/A
12/31/201721-45N/A-37N/A
9/30/201711-35N/A-35N/A
6/30/201711-34N/A-39N/A
3/31/20176-31N/A-41N/A
12/31/2016N/A-28N/A-39N/A
9/30/20160-24N/A-37N/A
6/30/20160-19N/A-27N/A
3/31/20161-16N/A-19N/A
12/31/20150-12N/A-12N/A
9/30/20152-8N/A-5N/A
12/31/20142-3N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XBRANE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: XBRANE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XBRANE is expected to become profitable in the next 3 years.

Revenue vs Market: XBRANE's revenue (25% per year) is forecast to grow faster than the Swedish market (4.2% per year).

High Growth Revenue: XBRANE's revenue (25% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: XBRANE's Return on Equity is forecast to be high in 3 years time (34.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/04 08:34
End of Day Share Price 2025/06/04 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Hans MählerNordea Markets
null nullNordea Markets